Ranbaxy gets approval for cefprozil in Canada

Cefprozil tablets and powder for oral suspension are indicated for the treatment of upper respiratory tract infections, uncomplicated skin and urinary tract infections. Cefprozil tablets were approved in 250mg and 500mg dose and the powder at 250mg/5mL.

“We are pleased to receive these approvals for cefprozil, tablets and powder for oral suspension to expand the number of product offerings that Ranbaxy commercializes for use by patients who require the therapeutic benefits of this product where indicated. This further adds to our expanding generic product portfolio which will have benefits of offering an affordable generic alternative to the brand that will now be accessible to all Canadians,” said Bill Abboud, president of RPCI.